We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+30.06%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$969M
AUM Growth
+$203M
Cap. Flow
+$35.5M
Cap. Flow %
3.66%
Top 10 Hldgs %
91.64%
Holding
30
New
3
Increased
5
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$48.2M
2
IVA
Inventiva
IVA
+$24.1M
3
RANI icon
Rani Therapeutics
RANI
+$12.8M
4
KLRS
Kalaris Therapeutics
KLRS
+$9.59M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$7.12M

Top Sells

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$16M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$15.7M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$10.3M
4
PVLA
Palvella Therapeutics
PVLA
+$8.94M
5
CTNM
Contineum Therapeutics
CTNM
+$5.69M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.07B
$304M 31.35%
6,897,652
+1,284,756
+23% +$48.2M
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.35B
$213M 21.98%
5,871,018
-392,133
-6% -$15.7M
KLRS
3
Kalaris Therapeutics
KLRS
$95.2M
$109M 11.27%
12,948,081
+1,500,000
+13% +$9.59M
SEPN
4
Septerna Inc
SEPN
$1.45B
$87.8M 9.06%
3,149,128
– –
ALMS
5
Alumis Inc
ALMS
$3.57B
$56.2M 5.8%
5,756,984
+955,614
+20% +$6.67M
NGNE icon
6
Neurogene
NGNE
$745M
$35.4M 3.65%
1,717,127
– –
IVA
7
Inventiva
IVA
$1.04B
$24.2M 2.49%
+5,194,805
New +$24.1M
GOSS icon
8
Gossamer Bio
GOSS
$68.9M
$22.4M 2.31%
7,222,559
+1,092,291
+18% +$3.12M
UPB
9
Upstream Bio Inc
UPB
$380M
$20M 2.06%
736,047
-226,107
-24% -$5.63M
AQST icon
10
Aquestive Therapeutics
AQST
$494M
$16.1M 1.67%
2,500,000
– –
JBIO
11
Jade Biosciences
JBIO
$1.2B
$14.9M 1.54%
968,798
+437,635
+82% +$5.13M
VTVT icon
12
vTv Therapeutics
VTVT
$128M
$11.9M 1.23%
298,496
-75,965
-20% -$2.11M
RANI icon
13
Rani Therapeutics
RANI
$77.1M
$11.5M 1.18%
+8,500,000
New +$12.8M
PVLA
14
Palvella Therapeutics
PVLA
$1.78B
$11M 1.13%
104,817
-104,817
-50% -$8.94M
ABVX
15
Abivax
ABVX
$11.5B
$10.2M 1.05%
75,442
– –
XFOR icon
16
X4 Pharmaceuticals
XFOR
$347M
$7.84M 0.81%
+1,960,000
New +$7.12M
NKTX icon
17
Nkarta
NKTX
$184M
$6.49M 0.67%
3,507,666
-260,369
-7% -$520K
ACLX
18
DELISTED
Arcellx
ACLX
$3.97M 0.41%
60,873
-20,292
-25% -$1.62M
STRO icon
19
Sutro Biopharma
STRO
$374M
$2.37M 0.24%
204,503
-15,178
-7% -$144K
CTNM
20
Contineum Therapeutics
CTNM
$506M
$826K 0.09%
72,245
-498,897
-87% -$5.69M
NUVB.WS
21
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$41K ﹤0.01%
124,119
-9,214
-7% -$2.02K
AURA icon
22
Aura Biosciences
AURA
$705M
– –
-584,849
Closed -$3.61M
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-675,504
Closed -$10.3M
BOLT icon
24
Bolt Biotherapeutics
BOLT
$8.59M
– –
-48,830
Closed -$260K
RYTM icon
25
Rhythm Pharmaceuticals
RYTM
$7.17B
– –
-30,285
Closed -$3.06M
1
2

Similar funds

OTL
Oak Thistle LLC New York $1.03B AUM 20.63% 1-Year Est. Return
TCM
Tributary Capital Management Omaha, Nebraska $1.03B AUM 19.64% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.03B AUM 16.43% 1-Year Est. Return

Samsara BioCapital's Q4 2025 Portfolio in Review

As of Q4 2025, Samsara BioCapital held 30 positions worth $969M, up 27% from $766M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Samsara BioCapital deployed $35.5M of net new capital in Q4 2025, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Inventiva: 5,194,805 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Mineralys Therapeutics, an estimated $15.7M trimmed.

  • Samsara BioCapital's largest Q4 2025 buy was Inventiva: 5,194,805 shares worth $24.2M.
  • Samsara BioCapital added most to Scholar Rock in Q4 2025, an estimated $48.2M increase.
  • Samsara BioCapital's biggest Q4 2025 reduction was Mineralys Therapeutics, cutting an estimated $15.7M.
  • Samsara BioCapital fully exited LENZ Therapeutics in Q4 2025, selling an estimated $16M.
  • Samsara BioCapital's ten largest holdings make up 92% of its $969M portfolio in Q4 2025.
  • Samsara BioCapital opened 3 new positions and closed 9 in Q4 2025.
  • Samsara BioCapital's portfolio value rose 27% quarter-over-quarter to $969M.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.